Cardiac AI: Do ECG Algorithms Actually Save Lives?

The hype around artificial intelligence in healthcare diagnostics often paints a picture of instant, perfect detection. But when you get down to the real-world performance of algorithmic electrocardiogram (ECG) screenings, especially for something as subtle and asymptomatic as low ejection fraction, the reality is a lot more nuanced than the marketing materials let on. For any health system investor or clinical advisor, the job is to cut through the aspirational claims by digging into the rigorous clinical evidence, or the lack of it.

Vertical AI Specialization in Cardiac Health

The AI healthcare field is splitting. You have general-purpose AI platforms on one side, and on the other, you’ve got vertical AI companies popping up that specialize in very specific diseases. This specialization is everything in cardiology, where understanding the faint physiological signals and the way a disease progresses requires deep, domain-specific expertise. Interpreting an ECG, for example, is so much more than simple pattern recognition. It means you have to understand cardiac pathophysiology, the immediate clinical context, and the subtle markers that appear long before any obvious symptoms. This is exactly where a disease-specific AI health platform (like one focused entirely on cardiac prevention) has a huge advantage. Their competitive edge is built on massive, labeled datasets for a single organ system, which lets them develop algorithms with the kind of superior specificity and sensitivity you need for cardiac conditions.

AI-ECG for Low Ejection Fraction: Unpacking the Mayo Clinic Trials

A huge area of focus for AI-ECG is detecting asymptomatic left ventricular dysfunction, specifically low ejection fraction (LEF), which is a major precursor to heart failure. The potential for a non-invasive test that’s already widely available to identify at-risk people before they show symptoms is immense. But taking a promising algorithm and turning it into something with real clinical impact requires a ton of rigorous validation. The Mayo Clinic has led the charge here, developing and validating AI algorithms that can detect LEF from a standard 12-lead ECG. Their research, particularly the study published in Nature Medicine, showed an AI algorithm could identify patients with reduced left ventricular ejection fraction with impressive accuracy Mayo Clinic Nature Medicine publication on AI-ECG for LEF. This initial work, which included the EAGLE trial published back in May 2021, showed AI’s potential as a screening tool for flagging individuals who might need further testing like an echocardiogram. After this success, Mayo Clinic licensed its ECG algorithms to Anumana, a company it co-founded with nference to bring these specialized AI tools into clinical practice. Anumana is a perfect example of the vertical AI model, concentrating only on cardiac AI applications. They’ve developed SaMD solutions that integrate these algorithms directly into existing clinical workflows, aiming for better early detection and intervention. Anumana’s ECG-AI LEF algorithm is FDA-cleared and available commercially in the US, after getting its FDA 510(k) clearance in October 2023. Anumana also got FDA clearances for its ECG-AI algorithms for pulmonary hypertension in March 2026 and cardiac amyloidosis in April 2026. Another company to watch in this space is AliveCor. AliveCor uses FDA-cleared ECG algorithms and is mostly known for its personal ECG devices that can spot atrial fibrillation. While their main game has been arrhythmia detection, their platform also shows how useful AI can be in reading single-lead ECGs for a range of cardiac issues. In January 2026, AliveCor got FDA clearance for the next generation of its KAI 12L AI which powers the Kardia 12L ECG System, to detect five more cardiac conditions, bringing its total to 39 cleared determinations. The whole FDA 510(k) clearance process is the regulatory gauntlet these companies have to run to bring these tools to market, and it ensures a baseline of safety and efficacy. FDA 510(k) clearance process for medical devices

Algorithmic Detection and Patient Survival: The Missing Link

While the technical accuracy of AI-ECG for identifying low ejection fraction is getting better documented, the billion-dollar question for health system investors and clinical advisors is this: Do algorithmic electrocardiogram screenings improve patient survival rates? Here, the conversation has to shift from diagnostic capability to clinical outcomes. The evidence we have now, while good for detection, is still a long way from drawing a direct, causal line to improved long-term survival. The Mayo Clinic trials and the validations that followed were mostly about the algorithm’s ability to identify the condition. A randomized controlled trial published in June 2025 did show that AI-ECG algorithms were effective at improving the early detection of low ejection fraction in routine hospital care and that the AI could boost diagnostic efficiency without jacking up healthcare utilization. That same study showed participants with a positive ECG-AI result were more than 20 times as likely to develop heart failure within three years as those with negative results. But what about the next steps? Everything that happens after the AI flags a patient, the physician’s actions, the patient’s adherence to treatment, and the overall impact on disease progression and mortality, are all complex variables that can only be untangled with extensive, multi-center, prospective studies with very long-term follow-up. To prove an AI-ECG tool actually improves patient survival, a company has to demonstrate that:

1. The AI-driven detection leads to earlier and more appropriate interventions.
2. These earlier interventions cause a statistically significant drop in adverse cardiac events and mortality compared to the standard of care.
3. The benefits clearly outweigh the potential harms or costs of more screening and all the downstream testing that comes with it. This means generating real-world evidence (RWE) from huge patient cohorts, tracking their outcomes over many years. Investors need to be asking if these companies are just showing off diagnostic accuracy or if they are truly validating the impact on patient-centric outcomes. Without a strong body of evidence showing improved survival, the value proposition is incomplete from a population health standpoint, no matter how compelling the diagnostic tech seems.
   

   Rigorous Multi-Center Testing and Reimbursement Pathways

   For any AI-driven diagnostic to get from the lab to widespread clinical adoption, it needs rigorous multi-center testing. This is the only way to demonstrate that the tool is generalizable across diverse patient populations, different clinical settings, and with all the various ECG equipment out there. You have to constantly worry about algorithmic drift. An AI model trained on data from a specific demographic can easily perform poorly when you deploy it in a different context. Monitoring for this drift and using a Predetermined Change Control Plan (PCCP) are absolutely necessary to maintain the model’s efficacy over time. On top of that, the economic viability of these vertical AI healthcare companies depends entirely on clear reimbursement pathways. The American Medical Association (AMA) issued new Category III CPT codes (0764T and 0765T) in 2023 for AI-powered ECG analysis to detect cardiac pathology, including low ejection fraction. Starting January 1, 2025, the Centers for Medicare & Medicaid Services (CMS) set a national hospital-outpatient payment for these codes (APC 5734), which was the first national reimbursement for AI-ECG detection of conditions like reduced ejection fraction. The 2026 CPT set adds even more codes for algorithmic ECG detection of cardiac dysfunction. This is the financial infrastructure that allows health systems to adopt and use these technologies without losing money. Without established reimbursement, even the most effective AI tool will just sit on a shelf. AMA CPT code process for new medical technologies

   Conclusion: Specialization and Outcomes Data are Key

   So for health system investors and clinical advisors, the takeaway is pretty clear: the future of AI that actually makes an impact in healthcare is in vertical specialization, and it has to be supported by strong clinical evidence based on patient outcomes. The diagnostic speed and accuracy of AI-ECG tools for identifying things like low ejection fraction are impressive, sure, but the only true measure of success is whether they help patients live longer. Companies like Anumana which are using specialized algorithms from top-tier institutions like the Mayo Clinic, are leading the way with this vertical approach. But any investment decision has to be anchored in verified, long-term impact on patient outcomes, proven through rigorous, multi-center clinical trials, and a clear path to getting paid. Anything less is a significant regulatory and commercial risk.